Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. (Ponnusamy S et al., Clin Cancer Res. 2019 Sep 3. PMID: 31481513)